The severity of oro-dental anomalies in patients with Loeys-Dietz syndrome segregates by gene mutations, according to a study published in the Journal of Medical Genetics.
The severity of oro-dental anomalies in patients with Loeys-Dietz syndrome (LDS) segregates by gene mutations, according to a study published in the Journal of Medical Genetics.
LDS is a rare connective tissue disorder characterized by vascular tortuosity, aneurysms, and craniofacial manifestations; it is classified into 6 subtypes based on associated gene mutations. The syndrome is caused by “mutations in genes encoding various components of the TGF-β signaling pathway: ligands, cell membrane receptors, and signal transducers,” according to the authors.
By examining the oro-dental features of 40 patients with LDS, from 5 subtypes, the researchers were able to assess the most severely affected subgroups.
“This extensive characterization, as well as some identified distinguishing features, can significantly aid dental and medical care providers in the diagnosis and clinical management of patients with this rare connective tissue disorder,” the researchers said.
The presence of a high-arched and narrow palate and enamel defects were the most common oro-dental manifestations among patients. Additional common characteristics included bifid uvula, submucous cleft palate, malocclusion, dental crowding, and delayed eruption of permanent teeth.
Researchers found, “Patients with TGF-β receptor II mutations [LDS2 subtype] presented with the most severe enamel defects, followed by patients with TGF-β receptor I mutations [LDS1 subtype]. LDS2 patients had a higher frequency of oro-dental deformities in general.” For this reason, the researchers concluded LDS2 has the most severely affected phenotype.
Less common oro-dental features among patients with LDS included presence of a bifid or broad uvula or submucous cleft, deep bite, dental crowding, and abnormal eruption pattern with a delay in the eruption of the permanent teeth.
Many rare diseases and genetic conditions have phenotypic manifestations presenting as dental anomalies. However, the researchers note this symptom is likely under-reported “as oro-dental anomalies and their impact on patients’ quality of life are often time overlooked as they are found in combination with other, more life-threatening, clinical manifestations.”
This study is the first of its kind to characterize common and distinguishing features of LDS subtypes. The authors note that future studies are needed on the ultrastructure and biomechanical properties of dental tissues from patients with LDS, in order to improve understanding of molecular and cellular mechanisms that lead to oro-dental anomalies.
Reference
Jani P, Nguyen QC, Almpani K, et al. Severity of oro-dental anomalies in Loeys-Dietz syndrome segregates by gene mutation [published online March 8, 2020].
J Med Genet. doi: 10.1136/jmedgenet-2019-106678.
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More